WELL Health Technologies (WELL.TO) Buy, Sell…

Home

Daily Stock Opinions and Ratings

WELL Health Technologies (WELL.TO)

4.34

+0.03 (0.70%)

as of Aug 25, 2026, 7:59:59 pm Market Open.

296 watching

Investor Insights

Aug 26, 2026, 12:00 am

This summary was created by AI, based on 14 opinions in the last 12 months.

WELL Health Technologies is experiencing a complex phase marked by significant strategic changes, including the divestiture of non-core US operations and the planned IPO of its technology subsidiary, Wellstar. Despite a strong revenue growth of 56% year-over-year and positive organic growth of 19%, the stock struggles with perception issues and volatile market sentiment. Many experts note that the market is in a wait-and-see mode, and the company needs to demonstrate clearer growth synergies and execution on its strategies. Although analysts have recognized its cheap valuation relative to earnings, underlying uncertainties regarding acquisitions and market dynamics pose risks. Overall, while the fundamentals may appear solid on paper, investor confidence seems fragile, necessitating patience and a clearer path to growth.

Consensus

Mixed

Valuation

Undervalued

Similar

Knight, KNT

COMMENT

Is in the online health service business, a huge growth area. It's a younger growth story without great cash flow but well positioned in Canada in the online health field. Doesn't own but is on his radar screen.

HOLD

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The stock price should not go below $3. 5i did not expect shares to go this low. Investors are not reacting to fundamentals recently. Nothing has changed for the company. More acquisitions should happen. Management is following their 5 year plan and doing a good job. Unlock Premium - Try 5i Free

HOLD

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The fundamental outlook has not changed. Their acquisition from 2021 is still to be proven. Sentiment is shifting towards telehealth with covid being less of a concern. Revenu growth should be good in 2022. The company is moving closer to profitability. Unlock Premium - Try 5i Free

HOLD

Electronic medical record software. Expectations are very high. Still in growth mode, so not profitable. Street's target is $11, with 60% growth expected next year. Overall, healthcare IT is an interesting space. Lots of competition. A hold. More research required before buying.

BUY ON WEAKNESS

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The entire sector has been weak. Investors have some reservations about dilution from the aggressive acquisition strategy. Still comfortable with the stock in the longer term. Unlock Premium - Try 5i Free

WEAK BUY

With covid, WELL and other tele health came into the spotlight. Their prices appreciated quickly. Now, we are seeing a move away with more competition and the vaccine. In terms of investing, there are better opportunities elsewhere. A good company in an industry that is growing, however.

DON'T BUY

Telehealth player, with more of an unfocused strategy. Whereas AKU is very focused.

BUY ON WEAKNESS

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. No concerns for the stock except for the short term volatility. The short report will affect it short term, but management is committed with no sellers. Insiders own 16%. Attractive around $5.75. Unlock Premium - Try 5i Free

DON'T BUY

He's closely watching the telehealth sector, which leapt ahead years during this pandemic. He prefers Teledoc. WELL is growing by buying businesses and adding customers, but it's a strategy he doesn't like, so he's put WELL on the backburner, but if they integrate these new companies well, WELL will do extremely well.

BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. They are in the midst of acquiring CRH. They will have more than $300M sales. Including expected growth, it looks much cheaper than it is. The company has lost money to date but is expected to make a profit this year. It must execute and is not risk free. Good growth potential. Unlock Premium - Try 5i Free

DON'T BUY

Canadian success story. Health technology play. A popular stock. Be cautious because of the valuation. Debatable if recent acquisition will be accretive. Trades at 35x forward EBITDA, so quite expensive.

COMMENT

WELL vs. TDOC He likes the industry, especially during Covid. A lot of efficiency gains have been unlocked with telehealth platforms. He prefers TDOC in the US, especially after its recent integration.

HOLD

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The market has shifted quickly recently. However, with an appropriate time frame, this stock should do fine. Nothing has changed fundamentally or at the company level. Though not risk free, the drop is market-related and not fundamental issues with the company. Unlock Premium - Try 5i Free

BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The acquisition of CRH is expected to be highly synergistic. There will be cross selling opportunities and a substantial presence in the US. It will attract new investors as it gets bigger. Unlock Premium - Try 5i Free

BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The US listing is generally positive. The move to be on the US index makes sense for a high growth company. Investors in the US are fine paying up front for future growth. Unlock Premium - Try 5i Free

Showing 61 to 75 of 80 entries

Most Recent Experts

Jason Del Vicario

HollisWealth

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

WELL Health Technologies (WELL.TO)